U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H30N2.2HO
Molecular Weight 236.3947
Optical Activity NONE
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEXAMETHONIUM HYDROXIDE

SMILES

[OH-].[OH-].C[N+](C)(C)CCCCCC[N+](C)(C)C

InChI

InChIKey=GYLUMIIRFKDCKI-UHFFFAOYSA-L
InChI=1S/C12H30N2.2H2O/c1-13(2,3)11-9-7-8-10-12-14(4,5)6;;/h7-12H2,1-6H3;2*1H2/q+2;;/p-2

HIDE SMILES / InChI
Hexamethonium is a nicotinic cholinergic antagonist. It was used to treat hypertension, but has never been approved and was discontinued because of the non-specified treatment. When this drug tried to use in medical study via inhalation, one of the volunteer died, the death has been described as “particularly disturbing ”because it was a healthy volunteer who had no thing to gain by taking part in the study. This volunteer participated in a study designed to provoke a mild asthma attack in order to help doctors discover the reflex that protects the lungs of healthy people against asthma attacks. Hexamethonium is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. Now it is widely used a research tool.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Nicotinic acetylcholine receptors
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

hypertensive crisis; acute ventricular failure in arterial hypertension; controlled hypotension.
Doses

Doses

DosePopulationAdverse events​
500 mg 1 times / day steady, oral
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Other AEs: Hypotension, Constipation...
Other AEs:
Hypotension (18 patients)
Constipation (18 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Constipation 18 patients
500 mg 1 times / day steady, oral
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Hypotension 18 patients
500 mg 1 times / day steady, oral
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Inhibition 20 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Hexamethonium, nicotinic receptor blocker, changes the neuronal reactions on glutamate in the medial septal area in vitro].
2007-06-29
The hexamethonium asthma study and the death of a normal volunteer in research.
2002-02
Modes of hexamethonium action on acetylcholine receptor channels in frog skeletal muscle.
1991-01
The interaction of hexamethonium with muscarinic receptor subtypes in vitro.
1989-10
Hexamethonium compounds in the treatment of hypertension.
1952-05-17
Patents

Patents

Sample Use Guides

intravenous: 5 to 50 mg; ora: 0.5 mg subcutaneous: 10-100 mg
Route of Administration: Other
In Vitro Use Guide
The action of hexamethonium has been studied at a range of muscarinic receptors in vitro by use of both functional and radioligand binding studies. In functional studies, hexamethonium exhibited little or no significant (P less than 0.05) antagonism of contractile responses to carbachol at muscarinic receptors in the guinea-pig ileum, oesophageal muscularis mucosae, urinary bladder and trachea. However, antagonism was observed at muscarinic receptors in the guinea-pig left atria mediating negative inotropic responses and the calculated pKB value was 3.80. Hexamethonium also antagonized contractile responses to carbachol in the canine saphenous vein. The pKB value at these receptors was 3.75. 3. In the presence of 3.2 mM hexamethonium, the pA2 value for methoctramine at atrial muscarinic receptors was reduced by approximately 10 fold (control pA2 value was 7.81 +/- 0.05; pA2 value in hexamethonium was 6.73 +/- 0.04).
Name Type Language
1,6-HEXANEDIAMINIUM, N1,N1,N1,N6,N6,N6-HEXAMETHYL-, HYDROXIDE (1:2)
Preferred Name English
HEXAMETHONIUM HYDROXIDE
Common Name English
Code System Code Type Description
FDA UNII
RVL393940Z
Created by admin on Mon Mar 31 22:26:40 GMT 2025 , Edited by admin on Mon Mar 31 22:26:40 GMT 2025
PRIMARY
PUBCHEM
6059
Created by admin on Mon Mar 31 22:26:40 GMT 2025 , Edited by admin on Mon Mar 31 22:26:40 GMT 2025
PRIMARY
CAS
556-81-0
Created by admin on Mon Mar 31 22:26:40 GMT 2025 , Edited by admin on Mon Mar 31 22:26:40 GMT 2025
PRIMARY